ObsEva SA (OBSV)

[INFINITI]

Yup

[PennyPusher786]

Sometimes these moves end up 100% up just from AH FOMO lol... i remember when the Chinese tickers were doing that in 2021..

Not in this market though... id be careful. I missed the 13s so i would suggest one consider dumping .20s

[INFINITI]

Busting a mi e here

[INFINITI]

No

[PennyPusher786]

Nah it's bottomed out and been getting volume for a few days.... i would be careful... existing shareholders will exit and new Shareholders may get caught holding bags if they drop it back to .10-.14 ...


What happened to your research? Did you find anything assuring? The share structure looks a little Fatt

[PennyPusher786]

Shorts get caught off guard here? Maybe it's a bait and trap

[INFINITI]

Looks like NEWS about to drop

[INFINITI]

Something is brewing here $$$

[INFINITI]

That’s a good thing

[TIMGZ]

JUST CHECK, NO HISTORY OF RS. GOOD THING! WILL KEEP YOU ABREAST. THANK YOU. GOOD LUCK WILL TODAY'S TRADING

[INFINITI]

It hit 52wk low so hopefully the climb back up starts

[INFINITI]

Not really just bought in still doing research

[TIMGZ]

VERY HONEST ANSWER, THANK YOU. FELT THE SAME. MAY BE WILL GET "TRKA" EFFECT. DO YOU HAVE ANY HISTORY ABOUT THE COMPANY. WHY RESTRUCTURING, BAD MANAGEMENT, RECKLESS OR WHAT

[INFINITI]

No reason Just got a hunch

[TIMGZ]

WHY? DUE TO. KINDLY ENLIGHTEN

[INFINITI]

Load up $$$$

[INFINITI]

Let’s goooo$$&$

[TrendTrade2016]

OBSV GAPPA WATCH

[Anite]

https://finance.yahoo.com/news/obseva-announces-sale-ebopiprant-license-120000808.html

Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 millionThe sale pro...

[INFINITI]

Why is this moving

[glenn1919]

OBSV...............................https://stockcharts.com/h-sc/ui?s=OBSV&p=W&b=5&g=0&id=p86431144783

[FLY HIGH NOW]

Here is the video why women are around the globe need OBSV products Now then ever ???? God bless Obsv products soon to be Available around the world ??????

[willlbone]

Might buy some mid 20s

[INFINITI]

Cheapies

[INFINITI]

Little reversal here

[AISI304]

Maybe a buyout candidate now with such weakness?
On watch for more slippage on this tough news. Yikes.

Cheap snack for some big-boy European pharma firm.
Have to see where the coming months take this. GLA

OBSV

[AISI304]

Any thoughts on how low this will go?
Dime? On watch for lower. GL to you.

OBSV

[Frankestin]

the use of the procedure seems aimed at reducing costs quickly!
It should be added but I don't like the management and they could bring it down a lot!
so I wait!
I certainly don't sell it I have 4.5k at $ 3.03
I don't think I'll see them again!
I think the dollar might take it back after the restructuring but I don't like everything I've seen so far!

[Frankestin]

the use of the procedure seems aimed at reducing costs quickly!
It should be added but I don't like the management and they could bring it down a lot!
so I wait!
I certainly don't sell it I have 4.5k at $ 3.03
I don't think I'll see them again!
I think the dollar might take it back after the restructuring but I don't like everything I've seen so far!

[Frankestin]

it is not a failure but it looks a lot like this!
I don't understand why they preferred to get to this point!
Why did they choose to finance themselves like this? In the end, it became convenient to leave the business close to the finish line!
I will wait for the renovation to finish!
Cursed be the ones who go short and the assholes who make them easier!


Obseva struggle for survival: the Genevan biopharmaceutical company specializing in the treatment of pathologies related to reproductive medicine and infertility intends to request a moratorium on composition and proceed with collective redundancies.

The company will undergo a profound restructuring, the leaders explain in a press release today. At the origin of the decision are the difficulties encountered by the company in the approval of its Linzagolix preparation, a drug for the treatment of uterine fibroids. The FDA, the American drug control authority, found gaps in the dossier. Obseva intends to provide the missing data and documents, but the process will incur costs. To meet these charges, a license agreement with a Japanese company is therefore revoked and various strategic options relating to the products in the portfolio will be analyzed.

[Frankestin]

well but here with news like this we could do + 100%!
Perhaps?
Only the vomit comes!
Here the administrators must have dared the inosable!
crazy stuff!

[Frankestin]

the temptation is great but I'm not selling!

[Frankestin]

ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix)

[Frankestin]

$ 1,77

[Frankestin]

how much patience here!

[Frankestin]

https://www.healio.com/news/womens-health-ob-gyn/20220509/video-linzagolix-is-a-winwin-for-patients-with-uterine-fibroids

[Frankestin]

after all it is a positive day, with news like this it could have done even -50%
instead for now only -0.5%.
at the moment
maybe it's because it's Friday 17th

[Frankestin]

Uterine fibroids are the most common benign pelvic tumors in women. Because many UFs are asymptomatic, estimating prevalence is difficult. 1 In a recent systematic review, prevalence estimates range from 4.5 to 68.6%, depending on study population and methodology, 2 with prevalence increasing with age until menopause, then declining. 1 This prevalence is higher than other conditions in women such as hypertension, 3 breast cancer, 4 or ovarian cancer. 5 There are marked differences by race in both prevalence and incidence ( Fig. 1 ), with age-specific incidence and prevalence of UF higher in black women at all ages. 1 2 Using ultrasound screening, the estimated cumulative incidence rate of UF by the age of 50 is significantly higher in black women (80%) compared with white women (nearly 70%).
a booger!
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193285/

[Frankestin]

let's scratch a little

[Frankestin]

[Frankestin]

The approval is based on positive data from the Company’s two Phase 3 PRIMROSE trials. The pooled week 24 data from these studies support a potentially best-in-class profile, with a responder rate of 84.5% in women receiving linzagolix 200 mg with hormonal ABT, and 56.5% in women receiving linzagolix 100 mg without ABT.

[Frankestin]

The NDA for linzagolix in the U.S. is currently under review by the FDA, with a PDUFA target action date of September 13, 2022

[Frankestin]

ObsEva today announced that the European Commission (EC) has granted marketing authorization for Yselty® (linzagolix), an oral GnRH antagonist, for the management of moderate to severe symptoms of uterine fibroids (UF) in adult women (over 18 years of age) of reproductive age.

[Frankestin]

http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220525:nGNE64Qrns&default-theme=true

[Frankestin]

Ms. Clancy commented, “I’m honored to be reprising the role of Chair at ObsEva at this pivotal time and building on the momentum created by Frank and the executive team as ObsEva prepares for commercial launch. My dedication to ObsEva and conviction in its prospects is long-standing, and I am excited to be presiding over this potentially transformational period as we pursue our first approvals and seek to change the treatment paradigm for women with uterine fibroids and other underserved conditions.”

Dr. Verwiel commented, “It is a privilege to have been part of the exceptional team at ObsEva over the past six years, and I take great pride in all that we have accomplished together. I look forward to following ObsEva’s continued achievement as the company nears prospective approval of linzagolix and pursues its vision of delivering life-changing therapies to address the most challenging unmet needs facing women.”

They almost almost buy some

[Frankestin]

Geneva, Switzerland and Boston, MA – April 7, 2022 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today published the invitation to its 2022 Annual General Meeting of Shareholders to be held on May 18, 2022 at 16:30 CEST at the company's offices in Geneva, Chemin des Aulx 12, 3rd floor, 1228 Plan-les-Ouates, Switzerland.

The agenda of the meeting will be as follows:

1 Approval of the Annual Report, the Statutory Financial Statements and theConsolidated Financial Statements for Fiscal Year 2021

The Board of Directors proposes that the annual report, the statutory financial statements and the consolidated financial statements of ObsEva SA for fiscal year 2021 be approved.

2 Discharge of Liability for the Members of the Board of Directors and of the Executive Committee

The Board of Directors proposes that shareholders release the members of the Board of Directors and of the Executive Committee from liability for their activities during fiscal year 2021.

3 Appropriation of Financial Results

The Board of Directors proposes that the loss of USD 55,480,053 for the financial year 2021 be appropriated as follows:

Financial Year 2021
Accumulated losses brought forward from previous year USD 328,451,570
Net loss for the year 2021 USD 55,480,053
Accumulated losses to be carried forward USD 383,931,623
4 Elections to the Board of Directors and Election of the Chairperson of the Board of Directors

[Pan_O_War]

ObsEva Announces First Quarter 2022 Financial Results and Corporate Update
[url]
https://www.obseva.com/pressrelease-detail/?pr=5000[/url][tag]insert-text-here[/tag]

https://www.obseva.com/pressrelease-detail/?pr=5000

[Pan_O_War]

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting

insert-text-here


https://www.obseva.com/pressrelease-detail/?pr=4963

[Frankestin]

https://www.globenewswire.com/news-release/2022/05/09/2438181/0/en/ObsEva-Presents-Clinical-Data-on-Oral-GnRH-Antagonist-Linzagolix-for-the-Treatment-of-Uterine-Fibroids-at-the-2022-ACOG-Annual-Clinical-and-Scientific-Meeting.html

We are encouraged by these additional analyses and post-treatment data from the PRIMROSE Phase 3 study that continue to underscore linzagolix's clinical utility and differentiated profile," said Dr. Brandi Howard, Chief Clinical Officer of ObsEva. "The results demonstrate that linzagolix has the potential to balance safety, efficacy, and address the wide-ranging symptoms of uterine fibroids. Linzagolix shows promise in delivering sustained clinical benefit, and if approved, would be the only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy to better address the individual needs of patients."

Ouch! Let's hope they won't punish her for the news

[Frankestin]

i hope no good news comes out!